Alira Health

Alira Health

Alira Health’s CDD Supports TVM Capital Healthcare Investment in DEBx Medical

We are pleased to have been an advisor on TVM Capital Healthcare’s investment in DEBx Medical. Following Alira Health’s Commercial Due Diligence (CDD), TVM Capital Healthcare, a global specialist healthcare private equity firm headquartered in Dubai and Singapore, has completed a multi-million euro investment in DEBx Medical, an Amsterdam-based medical devices company.

News
Published on:
October 18, 2023
We are very pleased that the investment by TVM Capital Healthcare will enable DEBx Medical to commence commercialization of its groundbreaking product for the benefit of patients. DEBx Medical has already successfully treated over 5,000 patients, and is about to introduce its product to the market.”
Dr. Michal Raciborski Managing Partner Financial Sponsors, Alira Health

The investment will accelerate the introduction of the DEBx Medical solution, DEBRICHEM®, an innovative product for treating non-healing chronic wounds that is easy to use and highly effective in removing biofilm and curing hard-to-heal wounds. Chronic wounds pose a significant healthcare challenge, have the potential for poor patient health and quality of life outcomes, represent a substantial cost to healthcare systems, and are particularly pronounced in the Gulf Cooperation Council (GCC) countries, where high levels of diabetes contribute to the problem. As part of the firm’s investment, DEBx Medical will establish a regional headquarter and a production base in the Middle East and North Africa area (MENA).

“We are very pleased that the investment by TVM Capital Healthcare will enable DEBx Medical to commence commercialization of its groundbreaking product for the benefit of patients,” said Dr. Michal Raciborski, Managing Partner Financial Sponsors at Alira Health. “DEBx Medical has already successfully treated over 5,000 patients, and is about to introduce its product to the market.”

“With this investment from our TVM Healthcare Afiyah Fund, we will accelerate the market introduction of a product which will transform the management of chronic wounds, and improve the life of millions of patients,” Tristan de Boysson, Managing Partner of TVM Capital Healthcare, commented. “This investment is also part of our Fund’s strategy of bringing innovative, best-in-class healthcare solutions to the wider MENA region.  We are looking forward to working together with the DEBx Medical management team.”

“We founded the company with the aim of innovating wound care, a market that has not seen significant innovation in a very long time,” Bert Quint, Co-founder and CEO of DEBx Medical, added. “Our product, DEBRICHEM®, has the potential to disrupt the chronic wound care market and help patients to heal fast, safely and effectively. After just one single treatment, more than 90% of chronic wounds start healing. TVM Capital Healthcare’s investment is testament to our technology, and we are looking forward to bringing our product to market together.”

For more information on Alira Health’s commercial due diligence and other consulting and clinical services enabled by technology and real-world evidence, visit AliraHealth.com.

Related news

Case Studies May 14, 2024
Medtech Company Creates an Early Go-to-Market Strategy for Its Breakthrough IVD Solution
The client needed an early go-to-market strategy for their IVD solution to prepare for product development and launch in key European countries and the US.
IVDR Medical Devices MedTech
Case Studies May 8, 2024
Mid-Size Medtech Company with a Borderline Product Defines Strategy for EU Launch
Medtech company sought support in developing a regulatory strategy for the EU launch of their product with an aggressive timeline to launch.
Medical Devices MedTech Regulatory
News May 6, 2024
Alira Health’s CDD Advises TVM Capital Healthcare Investment in neurocare Group AG
We are pleased to have been a Commercial Due Diligence advisor for an investment by TVM Capital Healthcare into neurocare group AG. The Munich-based leader in personalized mental health(...)
CDD Digital Therapeutics
News April 29, 2024
Alira Health Advises Trill Impact Entering a Strategic Alliance with TT medic
We are pleased to have been a Commercial Due Diligence advisor for Trill Impact, a pioneering Impact House with around EUR 1.2 billion in assets under management, joining forces with(...)
CDD CDMO MedTech
Events April 20, 2024
Symposium on Advanced Wound Care Spring 2024
Research & Development Wound Healing
Articles April 17, 2024
The Challenges for Medtech in a Complex Regulatory Landscape in 2024
Learn more about what manufacturers in the US and Europe should consider when developing their regulatory strategies and prioritizing their target markets from regulatory affairs expert Mercè Guerra.
Medical Devices MedTech Regulatory
News March 27, 2024
Alira Health Joins Forces with APMA to Advance Podiatric Registry
Alira Health joined the American Podiatric Medical Association (APMA), the largest professional association representing podiatrists, physicians and surgeons who treat the foot and(...)
Real-World Evidence (RWE) Registry-based studies Research and Development Wound Healing
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.